Aprogen Medicines Statistics

Total Valuation

Aprogen Medicines has a market cap or net worth of KRW 271.41 billion. The enterprise value is 656.13 billion.

Market Cap	271.41B
Enterprise Value	656.13B

Important Dates

The last earnings date was Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Aprogen Medicines has 266.09 million shares outstanding. The number of shares has decreased by -27.89% in one year.

Current Share Class	n/a
Shares Outstanding	266.09M
Shares Change (YoY)	-27.89%
Shares Change (QoQ)	+2.48%
Owned by Insiders (%)	8.04%
Owned by Institutions (%)	2.51%
Float	133.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.69
PB Ratio	2.34
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-13.47
EV / Sales	4.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.20

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.30.

Current Ratio	1.28
Quick Ratio	0.69
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-2.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -21.84% and return on invested capital (ROIC) is -10.12%.

Return on Equity (ROE)	-21.84%
Return on Assets (ROA)	-9.20%
Return on Capital (ROIC)	-10.12%
Revenue Per Employee	563.13M
Profits Per Employee	-181.72M
Employee Count	268
Asset Turnover	0.25
Inventory Turnover	1.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +13.08% in the last 52 weeks. The beta is 0.83, so Aprogen Medicines's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	+13.08%
50-Day Moving Average	1,224.22
200-Day Moving Average	1,294.18
Relative Strength Index (RSI)	33.98
Average Volume (20 Days)	2,390,266

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aprogen Medicines had revenue of KRW 150.92 billion and -48.70 billion in losses. Loss per share was -194.98.

Revenue	150.92B
Gross Profit	56.34B
Operating Income	-90.10B
Pretax Income	-88.27B
Net Income	-48.70B
EBITDA	-61.39B
EBIT	-90.10B
Loss Per Share	-194.98

Full Income Statement

Balance Sheet

The company has 68.01 billion in cash and 131.74 billion in debt, giving a net cash position of -63.73 billion or -239.51 per share.

Cash & Cash Equivalents	68.01B
Total Debt	131.74B
Net Cash	-63.73B
Net Cash Per Share	-239.51
Equity (Book Value)	432.56B
Book Value Per Share	435.58
Working Capital	38.09B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -44.99 billion and capital expenditures -19.31 billion, giving a free cash flow of -64.30 billion.

Operating Cash Flow	-44.99B
Capital Expenditures	-19.31B
Free Cash Flow	-64.30B
FCF Per Share	-241.66

Full Cash Flow Statement

Margins

Gross margin is 37.33%, with operating and profit margins of -59.70% and -32.27%.

Gross Margin	37.33%
Operating Margin	-59.70%
Pretax Margin	-58.49%
Profit Margin	-32.27%
EBITDA Margin	-40.68%
EBIT Margin	-59.70%
FCF Margin	-42.61%

Dividends & Yields

Aprogen Medicines does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	27.89%
Shareholder Yield	27.89%
Earnings Yield	-19.12%
FCF Yield	-23.69%

Stock Splits

The last stock split was on December 28, 2022. It was a reverse split with a ratio of 0.3333333333.

Last Split Date	Dec 28, 2022
Split Type	Reverse
Split Ratio	0.3333333333

Scores

Aprogen Medicines has an Altman Z-Score of -0.09. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.09
Piotroski F-Score	n/a